Eidos Therapeutics (NASDAQ:EIDX) is up 15.4% after hours following a filingthat shareholder BridgeBio Pharma (NASDAQ:BBIO) has made a nonbinding proposal to acquire the rest of the company’s shares.
The offer is for a fixed exchange ratio of 1.3 BridgeBio shares for each share of Eidos.
As of today’s close, that values Eidos shares at $38.77 each; the stock closed today at $32.06.
The filing discloses beneficial ownership of 66.6% of Eidos by BridgeBio.
BridgeBio is down 0.1% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.